ClinicalTrials.gg
Active, not recruitingNCT02411448RELAYUpdated Oct 6, 2026Results posted

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

A Phase 3 interventional study of Ramucirumab and Placebo in Metastatic Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 106 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 24
545 · median 74
Started
2015
with 1 other
Phase 3
3 of 24
none open now
Registered
7th of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 3, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B.

The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).
  • Eligible for treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation].
  • Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue samples other than stage IV NSCLC may be acceptable (optional for part C).
  • At least one .
  • of at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Known T790M EGFR mutation (not applicable for Part C Period 2).
  • Known , uncontrolled/unstable spinal cord compression, or .
  • Serious illness or medical condition.
  • Ongoing treatment with inducers or strong inhibitors.
  • Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.
  • History of gross hemoptysis.
  • Significant bleeding disorders.
  • Radiologically documented evidence of major blood vessel invasion or encasement by cancer.
  • Radiographic evidence of intratumor cavitation.
  • History of gastrointestinal perforation within last 6 months.
  • History of bowel obstruction, inflammatory enteropathy or extensive intestinal resection.
  • History of any arterial thrombotic event within 6 months prior to enrollment.
  • The participant has any known significant ophthalmologic abnormalities of the surface of the eye.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
545 participants (actual)

Study arms

  • Experimental
    Ramucirumab + Erlotinib

    Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met. Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Ramucirumab · Drug: Erlotinib

  • Placebo comparator
    Placebo + Erlotinib

    Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Placebo · Drug: Erlotinib

  • Experimental
    Ramucirumab + Gefitinib or Osimertinib

    Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally. * Ramucirumab and gefitinib administered during period 1. * Ramucirumab and osimertinib administered during period 2.

    Drug: Ramucirumab · Drug: Gefitinib · Drug: Osimertinib

Interventions

06

What researchers measure

Primary outcomes

  1. Part B: Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)

  2. Number of Participants With Treatment-Emergent Adverse Events

    A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

    Time frame: Cycle 1 Day 1 through End of Study (Up To 3 Years)

Secondary outcomes

  1. Part B: Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).

    Time frame: Randomization to Date of Death from Any Cause (Up To 37 Months)

  2. Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Randomization to Progressive Disease (Up To 37 Months)

  3. Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])

    DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.

    Time frame: Randomization to Progressive Disease (Up To 37 Months)

  4. Part B: Duration of Response (DoR)

    DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)

  5. Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

    Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

    Time frame: Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1

  6. Part B: Number of Participants With Anti-Ramucirumab Antibodies

    Part B: Number of Participants With Anti-Ramucirumab Antibodies.

    Time frame: Cycle 1 Predose through Follow-up (Up To 37 Months)

  7. Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)

    The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).

    Time frame: Baseline, End of Study (Up To 37 Months)

  8. Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

    The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

    Time frame: Baseline, Cycle 10 (each cycle is 2 weeks)

  9. Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

    The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

    Time frame: Baseline, Cycle 28 (each cycle is 2 weeks)

  10. Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

    The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

    Time frame: Baseline, Cycle 40 (each cycle is 2 weeks)

07

Results

Posted Mar 4, 2020

Participant flow

Participant flow — Overall Study
MilestonePart A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Started14224225
Received at least one dose of study drug14221225
Completed10141173
Not completed48352
Withdrew: Withdrawal by subject1149
Withdrew: Other020
Withdrew: Did not receive study treatment030
Withdrew: Alive on study treatment36443

Outcome measures

PrimaryPart B: Progression Free Survival (PFS)

PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Reported as:
Median · Months
Part B: Progression Free Survival (PFS)
MonthsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Progression Free Survival (PFS)19.4 (15.4 to 21.6)12.4 (11.0 to 13.5)
Statistical analysis
  • Part B: Ramucirumab+ Erlotinib vs Part B: Placebo+ Erlotinib · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.591 · 95% CI 0.461 to 0.760
PrimaryNumber of Participants With Treatment-Emergent Adverse Events

A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

Time frame:
Cycle 1 Day 1 through End of Study (Up To 3 Years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsPart A: Ramucirumab + ErlotinibPart B: Ramucirumab + ErlotinibPart B: Placebo + Erlotinib
Number of Participants With Treatment-Emergent Adverse Events14221225
SecondaryPart B: Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).

Time frame:
Randomization to Date of Death from Any Cause (Up To 37 Months)
Reported as:
Median · months
Part B: Overall Survival (OS)
monthsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part B: Ramucirumab+ Erlotinib vs Part B: Placebo+ Erlotinib · Log Rank · p = 0.4209 · Hazard ratio (hr): 0.832 · 95% CI 0.532 to 1.303
SecondaryPart B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Randomization to Progressive Disease (Up To 37 Months)
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
percentage of participantsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])76.3 (70.8 to 81.9)74.7 (69.0 to 80.3)
Statistical analysis
  • Part B: Ramucirumab+ Erlotinib vs Part B: Placebo+ Erlotinib · Cochran-Mantel-Haenszel · p = 0.7413
SecondaryPart B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])

DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.

Time frame:
Randomization to Progressive Disease (Up To 37 Months)
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participantsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])95.1 (92.3 to 97.9)95.6 (92.9 to 98.2)
Statistical analysis
  • Part B: Ramucirumab+ Erlotinib vs Part B: Placebo+ Erlotinib · Cochran-Mantel-Haenszel · p = 1.0000
SecondaryPart B: Duration of Response (DoR)

DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)
Reported as:
Median · months
Part B: Duration of Response (DoR)
monthsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Duration of Response (DoR)18.0 (13.9 to 19.8)11.1 (9.7 to 12.3)
Statistical analysis
  • Part B: Ramucirumab+ Erlotinib vs Part B: Placebo+ Erlotinib · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.619 · 95% CI 0.477 to 0.805
SecondaryPart B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

Time frame:
Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
microgram per milliliter (µg/mL)Part B: Ramucirumab+ Erlotinib
Cycle 239.6 ± 32
Cycle 468.5 ± 37
Cycle 785.7 ± 32
Cycle 1499.4 ± 31
SecondaryPart B: Number of Participants With Anti-Ramucirumab Antibodies

Part B: Number of Participants With Anti-Ramucirumab Antibodies.

Time frame:
Cycle 1 Predose through Follow-up (Up To 37 Months)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Number of Participants With Anti-Ramucirumab Antibodies1418
SecondaryPart B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)

The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).

Time frame:
Baseline, End of Study (Up To 37 Months)
Reported as:
Least squares mean · millimeter
Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)
millimeterPart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Loss of Appetite-17.07 ± 0.92-18.16 ± 0.91
Fatigue-19.35 ± 0.91-19.45 ± 0.90
Cough-21.22 ± 0.58-22.09 ± 0.57
Shortness of Breath-14.46 ± 0.57-15.93 ± 0.57
Blood in Sputum-1.58 ± 0.25-1.94 ± 0.25
Pain-13.57 ± 0.59-14.69 ± 0.59
Symptom distress-15.91 ± 0.67-16.15 ± 0.67
Interference with Activity Level-14.43 ± 0.83-15.60 ± 0.82
Global Quality of Life-16.21 ± 0.95-18.12 ± 0.94
Average Symptom Burden Index-12.17 ± 0.57-13.05 ± 0.57
Total LCSS-12.00 ± 0.62-12.71 ± 0.61
SecondaryPart B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

Time frame:
Baseline, Cycle 10 (each cycle is 2 weeks)
Reported as:
Mean · score on a scale
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
score on a scalePart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score0.02 ± 0.150.02 ± 0.15
SecondaryPart B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

Time frame:
Baseline, Cycle 28 (each cycle is 2 weeks)
Reported as:
Mean · score on a scale
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
score on a scalePart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score0.02 ± 0.180.01 ± 0.1
SecondaryPart B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.

Time frame:
Baseline, Cycle 40 (each cycle is 2 weeks)
Reported as:
Mean · score on a scale
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
score on a scalePart B: Ramucirumab+ ErlotinibPart B: Placebo+ Erlotinib
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score0.01 ± 0.15-0.01 ± 0.14

Adverse events

Collected over Up To 3 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Ramucirumab + Erlotinib2/14 (14.3%)0/14 (0%)14/14 (100%)
Part B: Ramucirumab + Erlotinib37/224 (16.5%)65/221 (29.4%)220/221 (99.5%)
Part B: Placebo + Erlotinib42/225 (18.7%)47/225 (20.9%)225/225 (100%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventPart A: Ramucirumab + ErlotinibPart B: Ramucirumab + ErlotinibPart B: Placebo + Erlotinib
PneumoniaInfections and infestations0/147/2211/225
CellulitisInfections and infestations0/144/2210/225
PneumothoraxRespiratory, thoracic and mediastinal disorders0/144/2213/225
PyrexiaGeneral disorders0/143/2214/225
DiarrhoeaGastrointestinal disorders0/143/2211/225
Hepatic function abnormalHepatobiliary disorders0/143/2212/225
Decreased appetiteMetabolism and nutrition disorders0/143/2210/225
Small intestinal haemorrhageGastrointestinal disorders0/142/2210/225
VomitingGastrointestinal disorders0/142/2211/225
Skin infectionInfections and infestations0/142/2210/225
Most frequent other events
Showing 10 of 161
Most frequent other events
EventPart A: Ramucirumab + ErlotinibPart B: Ramucirumab + ErlotinibPart B: Placebo + Erlotinib
DiarrhoeaGastrointestinal disorders13/14154/221160/225
ParonychiaInfections and infestations10/14118/221114/225
Dermatitis acneiformSkin and subcutaneous tissue disorders9/14149/221153/225
Dry skinSkin and subcutaneous tissue disorders9/1483/22191/225
Alanine aminotransferase increasedInvestigations7/1493/22170/225
HeadacheNervous system disorders7/1433/22116/225
HypertensionVascular disorders7/14100/22127/225
StomatitisGastrointestinal disorders6/1492/22182/225
AlopeciaSkin and subcutaneous tissue disorders6/1475/22144/225
Aspartate aminotransferase increasedInvestigations5/1492/22158/225

Baseline characteristics

All enrolled participants. Part C data will be reported after study completion.

Age, Continuous
Age, Continuous(years)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
Part A67.6 ± 13.2NA ± NANA ± NA67.6 ± 13
Part BNA ± NA63.7 ± 10.262.9 ± 10.663.3 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
Female11141142294
Male38383169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
Hispanic or Latino0131023
Not Hispanic or Latino1150160311
Unknown or Not Reported136155129
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
American Indian or Alaska Native0011
Asian7172174353
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White75248107
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
Romania0202
Hong Kong09615
United States0729
Japan7106105218
United Kingdom0437
Spain7231949
Canada0022
South Korea0252954
Turkey0347
Taiwan0263056
Italy081220
France04711
Germany07613
Geographic Region
Geographic Region(Participants)Part A: Ramucirumab + ErlotinibPart B: Ramucirumab+ ErlotinibPart B: Placebo+ ErlotinibTotal
East Asia7166170343
Other*75855120
08

Study locations

106 sites

Showing the first 100 of 106 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nishino K, Seto T, Nishio M, Nishio K, Kasahara K, Satouchi M, Yoh K, Hayashi H, Enatsu S, Matsui T, Varughese SC, Visseren-Grul C, Nakagawa K. RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC. Future Oncol. 2025 Oct;21(24):3197-3206. doi: 10.1080/14796694.2025.2560225. Epub 2025 Sep 25. PubMed 40995949 ↗
  • Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Moller B, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset. JTO Clin Res Rep. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819. eCollection 2025 Jun. PubMed 40458541 ↗
  • Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2025 Apr;20(4):487-499. doi: 10.1016/j.jtho.2024.11.032. Epub 2024 Nov 30. PubMed 39622410 ↗
  • Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study). Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub 2023 Aug 10. PubMed 37691865 ↗
  • Garon EB, Reck M, Nishio K, Heymach JV, Nishio M, Novello S, Paz-Ares L, Popat S, Aix SP, Graham H, Butts BD, Visseren-Grul C, Nakagawa K; RELAY study investigators. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open. 2023 Aug;8(4):101580. doi: 10.1016/j.esmoop.2023.101580. Epub 2023 Jun 28. PubMed 37390764 ↗
  • Chiu CH, Lin MC, Wei YF, Chang GC, Su WC, Hsia TC, Su J, Wang AK, Jen MH, Puri T, Shih JY. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Target Oncol. 2023 Jul;18(4):505-515. doi: 10.1007/s11523-023-00975-5. Epub 2023 Jun 17. PubMed 37329423 ↗
  • Nakagawa K, Garon EB, Gao L, Callies S, Zimmermann A, Walgren R, Visseren-Grul C, Reck M. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. Cancer Chemother Pharmacol. 2022 Aug;90(2):137-148. doi: 10.1007/s00280-022-04447-x. Epub 2022 Jul 16. PubMed 35841410 ↗
  • Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clin Res Rep. 2022 Feb 26;3(4):100303. doi: 10.1016/j.jtocrr.2022.100303. eCollection 2022 Apr. PubMed 35369607 ↗
  • Nadal E, Horinouchi H, Shih JY, Nakagawa K, Reck M, Garon EB, Wei YF, Kollmeier J, Frimodt-Moller B, Barrett E, Lipkovich O, Visseren-Grul C, Novello S. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug Saf. 2022 Jan;45(1):45-64. doi: 10.1007/s40264-021-01127-2. Epub 2021 Dec 20. PubMed 34928484 ↗
  • Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387. PubMed 34795131 ↗
  • Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. PubMed 31591063 ↗
  • Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21. PubMed 29317191 ↗
  • Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):96-99. doi: 10.1016/j.cllc.2016.05.023. Epub 2016 Jun 8. PubMed 27894601 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jan 2019, 44 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 44 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 8, 2015
StartActual
May 6, 2015
Primary completionActual
Jan 23, 2019
CompletionEst.
Dec 2026
Results first posted
Mar 4, 2020
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02411448
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
May 6, 2015
Primary completion
Jan 23, 2019
Completion
Dec 2026 (estimated)
Results posted
Mar 4, 2020
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Erlotinib · Osimertinib

Start the discussion